Ga naar hoofdinhoud

Bedaquiline resistance and the BPaLM regimen for RR-TB treatment

Knowledge gaps and translation from guideline to practice

24 jun 202212:00

Afbeelding 1/1

Rifampicin-resistant tuberculosis (RR-TB) remains a threat to global public health, with half a millions of RR-TB cases annually worldwide. Endorsement of WHO for the new BPaL(M) regimens based on the promising results of the TB-PRACTECAL trial brings new hope for RR-TB patients. This move underlines again the indispensability of bedaquiline (BDQ) for the treatment of RR-TB, yet the emergence of BDQ resistance and the current lack of accurate susceptibility tests for BDQ is posing a threat.

In this webinar, we will address several important questions. What did the PRACTECAL trial show? What is the burden of bedaquiline resistance? What are problems in diagnosing BDQ resistance? How can we overcome these challenges and use BDQ more effectively?

Register here!



  • Annelies Van Rie, Prof., MD., PhD.

Professor, Department of Family Medicine and Population Health, University of Antwerp, Belgium

Annelies Van Rie is a physician-scientist, epidemiologist and public health specialist. With more than 20 years of research experience, her expertise lies in molecular epidemiology of TB, the study of tuberculosis and HIV in resource poor settings and translate the knowledge gained into practice and action. Since 2016, she has headed The Tuberculosis Omics ResearCH (TORCH) consortium to build capacity in whole genome sequencing of tuberculosis and promote high quality ‘omics research on tuberculosis.



  • Catherine Berry, MD.

Clinical Advisor, Médecins Sans Frontières-UK, London, UK

Catherine Berry is an infectious diseases physician and conjoint lecturer with the University of Newcastle with a special interest in MDR-TB and antimicrobial resistance. She joined MSF in 2014, working on projects in Uzbekistan, Belarus, South Africa, and Jordan. She is the global principal investigator of the TB-PRACTECAL clinical trial which evaluated the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary MDR-TB.


  • Tom Decroo, MD., PhD.

Post-doctoral researcher, Unit of HIV & Tuberculosis, Institute of Tropical Medicine Antwerp, Belgium

Tom Decroo is a medical doctor who works as senior researcher at the Institute of Tropical Medicine of Antwerp. At the present he is involved in multiple research projects on the diagnosis and treatment of drug resistant TB.


  • Emmanuel Rivière, MSc.

Doctoral Research Fellow, Department of Family Medicine and Population Health, University of Antwerp, Belgium

Emmanuel Rivière is a PhD researcher at the University of Antwerp since 2017. He combines evolutionary biology with protein structural analyses and data science to investigate the resistance mechanisms of rare genetic mutations in the Mtb genome, with an emphasis on bedaquiline resistance.


  • Pham Hien Trang Tu, PharmD., MSc.

Research Fellow, Department of Family Medicine and Population Health, University of Antwerp, Belgium

Pham Hien Trang Tu is a young epidemiologist with background in Clinical Pharmacy. Obtaining the Master Degree in Epidemiology at University of Antwerp, she continues her research on the implementation and innovation of clinical decision-supporting tool for the treatment of RR-TB.